Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-4: Durvalumab or Placebo with SBRT in Unresected Stage I/II NSCLC, and Osimertinib Cohort
NCT03833154Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2019
- Primary completion
- Oct 2028
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 20
01
Overview
A Phase 3 trial of durvalumab, osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Mar 2019; status: active, not recruiting.
02
Drugs
durvalumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03833154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833154.